CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines-Reference-Cited by-同舟云学术

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines

Published:2018-11-08 Issue:3 Volume:173 Page:521-532
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Drögemöller Britt I., ,Wright Galen E. B.,Shih Joanne,Monzon Jose G.,Gelmon Karen A.,Ross Colin J. D.,Amstutz Ursula,Carleton Bruce C.^ORCID

Funder

Canadian Institutes of Health Research

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-5027-0/fulltext.html

Reference83 articles.

1. Global Burden of Disease Pediatrics Collaboration, Fitzmaurice C, Dicker D et al (2015) The Global Burden of Cancer 2013. JAMA Oncol 1:505–527. https://doi.org/10.1001/jamaoncol.2015.0735

2. Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6. https://doi.org/10.1186/bcr1639

3. Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205–213. https://doi.org/10.1038/nrd1031

4. Maximov PY, Lee TM, Jordan VC (2013) The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 8(2):135–155

5. Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7(1):46–53

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects;Biomedicine & Pharmacotherapy;2024-02

2. PAnno: A pharmacogenomics annotation tool for clinical genomic testing;Frontiers in Pharmacology;2023-01-26

3. The Use of Next-Generation Sequencing in Pharmacogenomics;Clinical Laboratory;2023

4. Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study;Journal of Modern Oncology;2022-11-25

5. Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism;Drug Metabolism and Disposition;2022-11-09